SCHEMBL5714934

SCHEMBL5714934

CC(C)(C)Cc1ccc2c(c1)[C]CCN2F

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714603 0.84 ESR1 (0.33) ESR1
SCHEMBL5714165 0.79 ESR1 (0.30) ESR1
SCHEMBL5714451 0.78 NOTUM (0.37)
SCHEMBL5713719 0.69 ESR1 (0.34) ESR1
SCHEMBL5713659 0.68 ESR1 (0.35) ESR1
SCHEMBL5714134 0.67 ESR1 (0.34) ESR1
SCHEMBL5713633 0.66 ESR1 (0.33) ESR1
SCHEMBL5713919 0.65 ESR1 (0.31) ESR1
SCHEMBL13547909 0.65 ALDH1A1 (0.51)
SCHEMBL3859373 0.63 ESR1 (0.43) ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1734961-A2 METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2006-12-27 EP claimed
WO-2005087714-A2 METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2005-09-22 WO claimed